BioCryst Pharmaceuticals (NASDAQ:BCRX) Downgraded to “Sector Perform” Rating by Royal Bank Of Canada

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by investment analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Thursday, MarketBeat Ratings reports. They presently have a $11.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada’s target price points to a potential upside of 24.86% from the stock’s current price.

BCRX has been the topic of several other reports. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 27th. JPMorgan Chase & Co. began coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 target price for the company. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 29th. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Finally, Wedbush cut their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.40.

BioCryst Pharmaceuticals Stock Down 2.8%

BCRX stock opened at $8.81 on Thursday. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.22. The stock’s 50 day moving average is $9.72 and its 200-day moving average is $9.23. The firm has a market capitalization of $2.25 billion, a PE ratio of -5.87 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The company had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. During the same quarter in the previous year, the firm earned $0.15 earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% on a year-over-year basis. On average, equities research analysts anticipate that BioCryst Pharmaceuticals will post -2.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Royal Bank of Canada increased its position in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in BioCryst Pharmaceuticals by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after buying an additional 8,517 shares during the period. Goldman Sachs Group Inc. grew its position in BioCryst Pharmaceuticals by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after buying an additional 640,704 shares during the period. Caxton Associates LLP purchased a new stake in BioCryst Pharmaceuticals during the first quarter worth about $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in BioCryst Pharmaceuticals by 11.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after buying an additional 47,355 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.